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PTEN negatively regulates mTORC2 formation and signaling
in grade IV glioma via Rictor hyperphosphorylation at
Thr1135 and direct the mode of action of an mTORC1/2
inhibitor
K Bhattacharya1,2, S Maiti1 and C Mandal
To investigate the role of PTEN (phosphatase and tensin homolog) in mammalian target of rapamycin complex 2 (mTORC2)
signaling in glioblastoma multiforme (GBM), we found higher activation of mTORC2 in PTENmu cells, as evidenced by enhanced
phosphorylation of mTOR (Ser2481), AKT (Ser473) and glycogen synthase kinase 3 beta (GSK3β) (Ser9) as compared with PTENwt
cells. In addition, PTENwt cells upon PTEN depletion showed mTORC2 activation. The reduced mTORC2 signaling in PTENwt cells was
related to higher Rictor phosphorylation at Thr1135 residue. Phosphorylation of Rictor at Thr1135 inhibited its association with
mTORC and thus there was a reduction in mTORC2 complex formation. In addition, PTENwt cells expressing mutated Rictor in which
Thr1135 was substituted with alanine, showed enhanced mTORC2 formation and signaling. This enhanced mTORC2 signaling
promoted inactivation of GSK3β. Thus, we established the reciprocal activation of mTORC2 and GSK3β in GBM. To the best of our
knowledge, this is the ﬁrst report describing role of PTEN in mTORC2 formation by promoting Rictor phosphorylation (Thr1135) in
GBM. Furthermore, the drug sensitivity of mTORC2 was evaluated. A newly identiﬁed carbazole alkaloid, mahanine, showed
cytotoxicity in both PTENmu and PTENwt cells. It inhibited both mTORC1/2 and AKT completely in PTENmu cells, whereas it inhibited
only mTORC1 in PTENwt cells. Cytotoxity and AKT-inhibitory activity of the mTORC1/2 inhibitor was increased either by depleting
PTEN or in combination with phosphatidylinositol 3 kinase inhibitors in PTENwt cells. In contrast, depletion of Rictor decreased the
cytotoxicity of the mTORC1/2 inhibitor in PTENmu cells. Thus, PTEN has an important role in mTORC2 formation and also inﬂuences
the effectiveness of an mTORC1/2 inhibitor in GBM.
Oncogenesis (2016) 5, e227; doi:10.1038/oncsis.2016.34; published online 30 May 2016
INTRODUCTION
Mammalian target of rapamycin (mTOR), a serine/threonine
(Ser/Thr) kinase protein, has a central role in cell growth and
proliferation.1,2 mTOR complex 1 (mTORC1) and complex 2
(mTORC2) are two functionally distinct complexes having some
common subunits.3–5 In addition, mTORC1 contains two more
speciﬁc subunits namely regulatory-associated protein of mam-
malian target of rapamycin (Raptor) and PRAS40.6–10 Rapamycin-
insensitive companion of mTOR (Rictor), mSin1 and protor1/2, are
exclusive partners of mTORC2.11–13 The binding of Rictor or Raptor
to mTOR is mutually exclusive in a certain cellular scenario.
mTORC1 promotes protein translation through activation of
S6K1, inhibition of 4E-BP1 and enhancement of RNA translation
via S6 ribosomal protein.2,14 mTORC2 can speciﬁcally phosphor-
ylate AKT at the Ser473 and take part in cell proliferation,
regulation and cytoskeletal reorganization.15,16 Rapamycin and its
analogs (rapalogs) are used for treatment of cancers as mTORC1
inhibitors. However, inhibition of mTORC1 induces the activation
of other survival pathways and thus reduces the efﬁcacy of
rapalogs.17–19 Therefore, targeting mTORC2 may possibly have
better therapeutic values.20 Accordingly, exploration of new
improved mTORC1/2 inhibitors is of great interest.
PTEN (phosphatase and tensin homolog), a tumor suppressor
protein, is often inactivated in cancers.21 Cellular cross-talk
between PTEN and mTORC1 via the phosphatidylinositol 3 kinase
(PI3K)/AKT/mTOR pathway is often deregulated and enhances the
malignancy.22,23 Although the role of mTORC1 is well character-
ized, the function and regulation of mTORC2 is still poorly
understood.
Glioblastoma multiforme (GBM) is a grade IV brain tumor
with higher mortality rate. PTEN, EGFR, TP53, CDKN2A, CDK4
and LOH are several frequently mutated genes.24 PTEN
mutations are frequently involved with this aggressive cancer,
our initial aim was to decipher the regulation of mTORC2
with respect to PTEN wild-type (PTENwt) vs mutated conditions
(PTENmu; Figure 1a). This information may help us to search
for an effective therapeutic strategy for disease management.
Earlier, we identiﬁed a non-toxic novel carbazole alkaloid
(mahanine), which induced apoptosis in several cancers includ-
ing GBM.25–32 Therefore, our next aim was to identify the mode
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of activity of mahanine as a possible mTOC1/2 inhibitor and
enhance the sensitivity based on cellular existence of
mTORC1/2.
Here we provide evidence for PTEN-mediated regulation of
mTORC2 in GBM. We showed that PTEN mutations lead to
reduced phosphorylation of Rictor at Thr1135, which in turn
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promotes enhanced mTORC2 formation and downstream signal-
ing. However, higher phosphorylation of Rictor at Thr1135 leads to
the reduction of mTORC2 formation in PTENwt cells. Furthermore,
we conﬁrmed a positive correlation between enhanced mTORC2
formation and sensitivity toward mahanine in PTEN-mutated cells.
Mahanine also inhibited mTORC1 activity and may thus be
considered as a potential mTORC1/2 inhibitor.
RESULTS
Differential mTORC1 and mTORC2 activity in PTENwt and PTENmu
cells
To understand the impact of functional PTEN in mTORC2
formation and downstream signaling, we selected PTENmu
(U87MG) and PTENwt (LN229) GBM cells and the status of PTEN
was veriﬁed (Figure 1b). Next, we examined the status of speciﬁc
phosphorylation of mTOR complexes. Active mTORC2-speciﬁc
phosphorylation of mTOR at Ser2481 was higher in PTENmu cells
(Figure 1c). In contrast, mTORC1-speciﬁc phosphorylation at
Ser2448 was almost comparable in PTENwt and PTENmu cells.
However, Rictor and Raptor, two major mTORC2 and mTORC1-
associated proteins were very similar in both the cells. This result
indicates probable activation of mTORC2 because of PTEN
mutation.
To conﬁrm this upstream activation of mTORC2 in PTENmu
cells, we examined the phosphorylation status of a few down-
stream molecules. Ser473 of AKT is a selective substrate of
mTORC2. We observed enhanced expression of phospho-AKT at
Ser473 in PTENmu cells (Figure 1d). As mTORC2 is not known to
inﬂuence the Thr308 of AKT, we detected almost comparable
levels of phosphorylation in both PTENwt/PTENmu cells (Figure 1e).
In addition, no signiﬁcant change of AKT phosphorylation
at the Thr450 was found. Densitometric analysis of three
phosphorylation sites of AKT revealed that only Ser473 was
~ 5-fold enhanced in PTENmu cells relative to PTENwt (Figure 1f).
This observation strongly suggested that PTEN mutation may
have a signiﬁcant role in regulating mTORC2 activity, which in
turn enhanced the phosphorylation of its substrate AKT at the
Ser473.
To conﬁrm the activation of AKT through its Ser473 phosphor-
ylation, next we focused on GSK3β. Activated AKT phosphorylates
GSK3β at the Ser9 position and induces its inactivation.
Phosphorylation of GSK3β at Ser9 was higher in PTENmu cells,
indicating the sequential signaling of activated mTORC2 and AKT
and subsequent inactivation of GSK3β (Figure 1g). This result
suggested the reciprocal relationship of mTORC2 and GSK3β. In
contrast, mTORC1 activity was similar in both PTENmu/PTENwt cells
as judged by the equivalent phosphorylation of S6K1 at Thr389
and 4E-BP1 at Thr37/46 (Figure 1h).
Knockdown of PTEN enhances mTORC2 signaling in PTENwt cells
To further conﬁrm the role of PTEN in mTORC2 activity, we
transiently knocked down PTEN using targeted short interfering
RNA (siRNA) in PTENwt cells (Figure 2a), which exhibited ~ 4-fold
increase in mTORC2-speciﬁc phosphorylation of mTOR at Ser2481
(Figures 2b and c), demonstrated by the western blot analysis. This
result supported our initial observation in PTENmu cells (Figure 1),
conﬁrming the activation of mTORC2 in the absence of wild-type
PTEN. The downstream substrate of mTORC2 (Ser473 of AKT) was
also highly phosphorylated upon PTEN depletion (Figures 2d and e)
and the inhibitory Ser9 phosphorylation of GSK3β was also
enhanced (Figures 2f and g). These ﬁndings reconﬁrmed the
reciprocal activation proﬁle of mTORC2 and GSK3β. We have also
observed the enhanced phosphorylation at Thr308 (substrate of
PDK1) of AKT upon PTEN knockdown (Figures 2d and e). This
served as a positive control for PTEN deactivation and subsequent
activation of the PI3K pathway, which in turn activated mTORC1 as
evidenced by increased mTOR phosphorylation at Ser2448
(Figures 2b and c). As mTORC1 activity is regulated by the PI3K
pathway, therefore we next studied the phosphorylation of S6K1
and 4E-BP1. We observed hyperphosphorylation of S6K1 at Thr389
and 4E-BP1 at Thr37/46 after knockdown of wild-type PTEN
(Figures 2h and i).
Identiﬁcation of Rictor as the target molecule of PTEN for mTORC2
signaling
As binding of Rictor to mTOR is the major determining factor for
mTORC2 signaling, we wanted to address its role in the PTEN-
mutated and/or depleted conditions. Accordingly, we transiently
knocked down the expression of Rictor by targeted siRNA in the
PTENmu cells (Figure 3a). Upon Rictor depletion, mTORC2
activation was diminished as evidenced by decreased Ser2481
phosphorylation of mTOR (Figures 3b and c). Subsequently, the
speciﬁc downstream pathway was also hampered as evidenced by
the decreased phosphorylation of Ser473 for AKT (Figures 3d and e)
and Ser9 for GSK3β (Figures 3f and g). The relationship between
mTORC2 inactivation and corresponding GSK3β activation was also
observed after Rictor depletion. This data indicated that upon PTEN
deactivation, Rictor is essential for the functional activation of
mTORC2 and subsequent downstream signaling.
Next, PTENwt cells were transfected with siRNA for PTEN or co-
transfected with siPTEN and siRictor. Both the single- and double-
knockdown of PTEN/Rictor was conﬁrmed (Figure 3h). PTEN
knockdown enhanced the overall mTORC2 signaling molecules as
observed before (Figure 2). However, when Rictor and PTEN were
depleted, the mTORC2 signaling was comparatively reverted.
Thus, PTEN knockdown-mediated enhanced phosphorylation of
mTOR (Ser2481), AKT (Ser473), and GSK3β (Ser9) were decreased
upon Rictor depletion. Therefore, our observation conﬁrmed that
Figure 1. Differential activation of mTORC1 and mTORC2 in PTENwt and PTENmu GBM cells along with downstream signaling. (a) Schematic
representation of proposed hypothesis: role of PTEN in mTORC2 signaling pathways. (b–h) PTENmu and PTENwt cells were harvested and lysed
and kept in phosphate-buffered saline (PBS) with protease and phosphatase inhibitors. Protein concentrations were measured by the
Bradford’s protein assay reagent. Proteins (50-100 μg) from each sample were resolved in sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS–PAGE; 5–12%) followed by electrotransfer into nitrocellulose/polyvinylidene diﬂuoride (PVDF) membrane and probed
with primary antibodies (1:1000–1:2000) and incubated overnight at 4 oC. Then the membrane was washed with Tween-20 (0.1%) containing
Tris-buffered saline (TBS) and incubated with horseradish peroxidase-conjugated secondary antibodies (1:1000). They were washed and target
proteins were identiﬁed by the West Pico chemiluminiscence detector system or Biorad ChemiDoc MP System (Bio-Rad). Developed bands of
corresponding proteins were densitometrially analyzed by ImageJ software. (b) Level of PTEN in PTENmu and PTENwt cells. (c) Status of mTOR,
p-mTOR Ser2448, p-mTOR Ser2481, Rictor and Raptor. (d) AKT, the downstream substrate of mTORC2 was highly phosphorylated at Ser473 in
PTENmu cells. (e) Status of AKT phosphorylation at the Thr450 and Thr308 positions. (f) Densitometric analysis showed phosphorylation of AKT
at the Thr450, Thr308 and Thr 473 sites. Values were normalized against the relative expression of β-actin and total AKT, quantiﬁed by ImageJ
software. Each value was the mean± s.d. of three independent experiments. *Po0.05, signiﬁcant difference between two test groups. (g)
Status of Ser9 phosphorylation of GSK3β, the substrate of activated AKT. (h) mTORC1 activity readout as identiﬁed by phosphorylation of S6K1
and 4E-BP1. β-Actin served as loading control for all the western blots.
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Rictor is an essential molecule upon PTEN inactivation for mTORC2
signaling. However, in the absence of Rictor, the basal level
phosphorylation of AKT (Ser473) was possibly maintained by AKT
autophosphorylation. The literature has shown that AKT can be
autophosphorylated (Ser473) by the activation of the AKT kinase
domain because of phosphorylation at Thr308.33 Therefore, even
after depletion of Rictor, a basal level of Ser473 phosphorylation
was observed.
We next addressed whether this mechanism was consistent
across other GBM cells namely T98G (PTENmu), U373MG (PTENmu)
and LN18 (PTENwt). Both PTENmu cells were hyperactive in
mTORC2 signaling as reﬂected by higher phosphorylation of
Figure 2. Knockdown of PTEN from PTENwt GBM cells enhances the mTORC2 signaling pathway. PTENwt cells were transfected with targeted
siRNA against PTEN. After 24 h of transfection, cell lysates were subjected to western blot analysis. (a) Status of PTEN after siRNA transfection
in PTENwt cells. (b) Expression of mTOR and p-mTOR were determined by speciﬁc antibodies. (c) Densitometric analyses mTOR and p-mTOR
blots. (d) Phosphorylation of AKT at Ser473 and Thr308 residues with respect to total AKT. (e) Densitometry values of AKT at Ser473. (f) Status
of GSK3β phosphorylation at Ser9 residue. (g) Relative densitometry value of GSK3β Ser9 western blot. (h) mTORC1 activity readout judged by
the phosphorylation of its downstream substrate 4E-BP1 and S6K1. (i) Fold change of p-S6K1 and p-4E-BP1 showed with relative densitometry
analysis. β-Actin was served as loading control in all set of experiments. All the densitometric analysis was done by ImageJ software and
normalized against the expression of β-actin and respective total protein level. The protein levels from three independent experiments were
quantiﬁed and presented as mean± s.d. Asterisk indicates signiﬁcant difference when compared with the control (Po0.05).
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mTOR (Ser2481) in contrast to PTENwt (Figure 3i). Downstream
substrates (Ser473 of AKT and Ser9 of GSK3β) were also
hyperphosphorylated, suggesting that this may be a general
phenomenon of PTEN-dependent mTORC2 activation in GBM.
Functional existence of PTEN negatively regulates mTORC2
complex formation
After identifying the importance of Rictor in PTEN-mutated
and/or depleted conditions, we asked an obvious question
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about the interconnection between mTOR complex formation
and differential signaling of mTORC2 in PTENwt/PTENmu cells.
A co-immunoprecipitation experiment showed that mTOR was
associated with Raptor almost equivalently, indicating a similar
level of mTORC1 formation in both cells (Figure 4a). In contrast,
mTOR was predominantly associated with Rictor only in PTENmu
cells, demonstrating differential mTORC2 formation between
these two cells.
For further reconﬁrmation, we depleted PTEN from PTENwt cells
using siRNA targeting PTEN and observed a signiﬁcant association
between mTOR and Rictor in deﬁciency of PTEN, suggesting
formation of mTORC2 (Figure 4b). This result suggested that PTEN
in active form not only suppresses the mTORC2 signaling but also
inhibits the Rictor-dependent mTORC2 complex formation.
PTEN inhibits mTORC2 formation by stimulating Rictor (Thr1135)
phosphorylation
We then addressed the cause of reduced recruitment of Rictor to
mTORC in the presence of functional PTEN. Phosphorylation of
Rictor (Thr1135) is known to inhibit mTORC2 activity as evidenced
by decreased AKT Ser473 phosphorylation.34 Accordingly, we
addressed whether this phosphorylation was differentially regu-
lated between PTENwt and PTENmu cells. Our results revealed that
phosphorylation of Rictor at the Thr1135 were signiﬁcantly higher
in PTENwt cells (Figure 4c). To investigate whether the presence of
functional PTEN had any relevance for Rictor Thr1135 phosphor-
ylation, we transiently knocked down PTEN in PTENwt cells. These
knockdown cells exhibited decreased phosphorylation at Thr1135
of Rictor (Figures 4d and e). This result suggested an involvement
of PTEN with Rictor hyperphosphorylation at the Thr1135, which in
turn possibly inhibits Rictor’s association with mTOR, and we
observed reduced mTORC2 formation and lower mTORC2 activity.
Considering this, we checked the status of Rictor phosphorylation
in other PTENmu/PTENwt cells, and other PTENmu cells also showed
a lower level of Rictor (Thr1135) phosphorylation compared with
PTENwt (Figure 4f), consistent with Figure 3i. These ﬁndings
support our hypothesis that higher phosphorylation of Rictor is
responsible for reduced recruitment to mTORC.
To conﬁrm our ﬁndings, we next transfected PTENwt cells with
either wild-type pRK-5/Rictor (myc-tag), the T1135A mutant of
pRK-5/Rictor (myc-tag) or the empty vector alone and checked the
association of exogenous Rictor and endogenous mTOR by
co-immunoprecipitation. Cells expressing mutated Rictor (T1135A)
showed enhanced association with endogenous mTOR in
comparison with wild-type Rictor/empty vector-transfected cells
(Figure 4g). In addition, the level of myc-tag Rictor was equivalent
in both wild-type and mutated transfections (Figure 4h). Western
blot also revealed that phosphorylation of AKT (Ser473), GSK3β
(Ser9) and mTOR (Ser2481) were increased in cells transfected
with mutant Rictor (T1135A), indicating higher mTORC2 signaling.
These data conclusively established that functional PTEN inhibit
mTORC2 formation by promoting Rictor (Thr1135) phosphoryla-
tion (Figure 4i).
However, it is unusual that one phosphatase can induce
hyperphosphorylation. It has been reported that S6K1 is
responsible for the phosphorylation (Thr1135) of Rictor. Earlier,
we found that upon PTEN depletion there was an increase in S6K1
phosphorylation (Thr389), that is, the signature of active S6K1
(Figures 2h and i). Accordingly, we hypothesized that upon PTEN
depletion in PTENwt cells, the decrease in Rictor phosphorylation
(Thr1135) may revert back because of the increased activity of
S6K1. Therefore, the actual effects of PTEN were masked by the
increased activity of S6K1. To reveal the deﬁnite effects of PTEN
depletion upon Rictor phosphorylation, we ﬁrst inhibited the S6K1
phosphorylation by disrupting active mTORC1 formation, as
mTORC1 is responsible for phosphorylation of S6K1. To inhibit
mTORC1 activity, we knocked down Raptor in the PTENwt cells and
observed reduced phosphorylation of both S6K1 (Thr389) and
mTOR (Thr2448) (Figure 4j). In consequence, the phosphorylation
of Rictor (Thr1135) was decreased and mTOR phosphorylation
(Thr2481) was increased, indicating S6K1 mediated possible
inactivation of mTORC2 (Figures 4j and k). Simultaneous depletion
of both Raptor and PTEN from PTENwt cells triggered a complete
reduction in Rictor Thr1135 phosphorylation as well as increased
phosphorylation of mTOR (Thr2481). Thus, PTEN depletion
coupled with S6K1 deactivation enhances mTORC2 activity
through Rictor dephosphorylation (Thr1135).
Mahanine behaves as a mTORC1/mTORC2 inhibitor, acting
differentially in PTENmu and PTENwt cells
Identiﬁcation of differential mTORC signaling was the foundation
for the development of chemotherapeutic agents. We previously
identiﬁed mahanine as a potential chemotherapeutic agent for
GBM (Supplementary Figure S1).25 It displayed a cytotoxic effect
against PTENmu and PTENwt cells (Supplementary Figure S2). Here
we observed that mahanine suppressed both Ser2448 and
Ser2481 phosphorylation of mTOR in PTENmu cells, whereas only
Ser2448 phosphorylation was inhibited in PTENwt cells (Figure 5a).
Owing to the low level of Ser2481 phosphorylation of mTOR in
PTENwt cells, mahanine-mediated regulation was almost unde-
tectable. This result indicated that mahanine act as both an
mTORC1 and mTORC2 inhibitor in PTENmu/PTENwt cells, depend-
ing on the existence of those complexes.
To conﬁrm this mTOR-inhibitory mechanism of mahanine, we
studied its downstream AKT pathway. Mahanine-treated PTENmu
cells exhibited decreased phosphorylation at Thr308 and Ser473
when both mTORC1 and mTORC2 were present (Figure 5b).
However, mahanine behaved similarly in both PTENmu and PTENwt
by inducing downregulation of 4E-BP1 in total protein level and
phosphorylated forms but phosphorylation of S6K1 (Thr389) was
decreased only in PTENmu cells in contrast to PTENwt, where
phosphorylation at this site was increased (Figure 5c).
Although mahanine showed cytotoxicity in PTENwt cells, we did
not observe any inhibition of AKT phosphorylation (Thr308 and
Ser473) when mTORC2 was not in signiﬁcant level and mainly
mTORC1 was present (Figure 5b). Therefore, mahanine was
Figure 3. Rictor is essential for mTORC2 signaling upon PTEN mutation. (a–g) PTENmu cells were transfected with siRictor. After 24 h of
transfection, cell lysates were prepared and subjected for western blot analysis. (a) Expression of Rictor was determined. (b, c) Level of
mTORC-speciﬁc phosphorylations were shown in western blot with relative densitometry values. (d, e) mTORC2 activity was checked by
studying Ser473 phosphorylation of AKT. Relative densitometry analysis of AKT ser473 showed. (f, g) Status of GSK3β Ser9 phosphorylation
with relative densitometric analysis. (h) PTENwt cells were transfected with siPTEN or co-transfected with both siPTEN and siRictor
consecutively. After 24 h of transfection, cell lysates were prepared and subjected for western blot analysis. Western blots showed that
knockdown of Rictor from PTEN-depleted cell reverted mTORC2 signaling pathway. Single knockdown of PTEN increased phosphorylation of
mTOR (Ser2481), AKT (Ser473) and GSK3β (Ser9). Depletion of both PTEN and Rictor decreased phosphorylation of mTOR (Ser2481), AKT
(Ser473) and GSK3β (Ser9). (i) Status of p-AKT (Ser473), p-GSK3β (Ser9) and p-mTOR (Ser2481) with respect to total protein level in other
PTENmu (T98G, U373MG) and PTENwt (LN18) GBM cell lines. β-Actin was served as loading control in all set of experiments. All the
densitometric analysis were done by ImageJ analysis and normalized against the expression of β-actin and respective total protein level. Each
value is the mean± s.d. of three independent experiments. *Po0.05, signiﬁcant difference between two test groups.
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possibly inducing cell death in PTENwt cells by targeting other
pathways. Inhibition of mTORC1 releases the feedback inhibition
mediated by the S6K1-IRS1-PI3K loop, which leads to activation
of the AKT pathway in cancer.35 Accordingly, we inhibited the
PI3K pathway using two speciﬁc inhibitors, wortmannin and
LY294002, separately to check the status of AKT activation in
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mahanine-treated PTENwt cells. Mahanine, even at a low dose,
exhibited reduced AKT phosphorylation at Thr308 and Ser473
sites in the presence of these inhibitors, suggesting involvement
of the PI3K pathway in AKT activation in PTENwt cells (Figures 5d
and e). We also checked other downstream effector molecules of
mTORC1 and observed phospho-S6K1 (Thr389) and 4E-BP1
(Thr37/46) were reduced signiﬁcantly when the mTORC1/2
inhibitor was used in combination with wortmannin as compared
with the inhibitor alone (Figure 5e). Furthermore, the mTORC1/2
inhibitor with LY294002 or wortmannin synergistically enhanced
the cell death in PTENwt cells compared with the inhibitor alone
(Figures 5f and g). Overall, we demonstrated that, in the PTENwt
condition, where mTORC1 formation was predominant and
mTORC2 was not present in signiﬁcant amount, this mTORC1/2
inhibitor behaved like an mTORC1 inhibitor and enhanced the
AKT-mediated cell protective pathway, which could be reverted by
PI3K inhibition.
A therapeutic strategy to treat GBM by suppressing native PTEN to
enhance the activity of the mTORC1/2 inhibitor
Next, we addressed the role of PTEN in activation of AKT in
mahanine-treated PTENwt cells. We depleted PTEN from the
PTENwt cells and observed the effect of the mTORC1/2 inhibitor.
Western blot analysis revealed that the mTORC1/2 inhibitor could
inhibit AKT activation, identiﬁed by a reduction in phosphorylation
in PTENwt cells when the PTEN was depleted by siRNA (Figure 6a).
The activity of the mTORC1/2 inhibitor in PTEN-depleted PTENwt
cells was enhanced, as identiﬁed by the increased propidium
iodide (PI) positivity compared with mock-transfected cells
(Figure 6b). This is possibly because PTEN depletion induces
generation of mTORC2 as a target complex. This result indicated
that the mTORC1/2 inhibitor exhibited more effects when PTEN is
mutated and subsequently mTORC2 is activated.
To conﬁrm our ﬁndings, we next inhibited mTORC2 formation in
PTENmu cells by depleting Rictor and then treated with mahanine.
We observed decreased PI positivity when there was a reduction
in mTORC2 activity (Figure 6c). Microscopic images also proved
that the mTORC1/2 inhibitor has a signiﬁcantly lowered cytotoxic
effect after Rictor knockdown (Figure 6d). Therefore, we con-
cluded that cells having enhanced mTORC2 are more sensitive to
the mTORC1/2 inhibitor. Our overall ﬁndings established that, as in
PTENwt cells, no signiﬁcant mTORC2 formation were occurring, so
the mTORC1/2 inhibitor-induced AKT activity was driven by the
sole inhibition of mTORC1. Upon PTEN depletion, they behave like
a dual mTORC1/2 inhibitor because of the formation of enhanced
mTORC2 as a target molecule (Figure 6e). On the contrary, Rictor
depletion inhibits mTORC2 formation, made PTENmu cells less
sensitive to the mTORC1/2 inhibitor. Thus, PTEN has an important
role in mTORC2 formation and also inﬂuences the effect of an
mTORC1/2 inhibitor in GBM.
mTORC2 formation showed reduced sensitivity to a GSK3β
inhibitor
Along with mTORC1/2, GSK3β has long been a chemotherapeutic
target in GBM. We had identiﬁed a signiﬁcant reciprocal activation
between mTORC2 and GSK3β (Figures 1g and 2f). In PTENmu cells,
mTORC2 was activated and GSK3β was inactivated, whereas in
PTENwt cells the situation was the reverse. To check the
functionality of this observation, we performed a cell death assay
and observed that a speciﬁc GSK3β inhibitor (SB216763) showed
lower PI positivity, indicating lower cell death in PTENmu cells
compared with PTENwt (Figure 6f). We hypothesized that in
PTENmu cells, GSK3β was already inhibited by a higher level
phosphorylation (Ser9) and therefore the addition of a GSK3β-
inhibitor did not exert any extra effect. In contrast, an mTORC1/2
inhibitor (mahanine) exhibited signiﬁcantly enhanced cytotoxicity
in PTENmu cells. This was further conﬁrmed by demonstrating
higher G0/G1 phase cell cycle arrest (Figure 6g). These results
validated that, depending on PTEN status, mTORC2 and GSK3β
maintain a reciprocal relationship. Cells, which are susceptible to
mTORC2 inhibition, may not be susceptible to GSK3β inhibition
and vice versa (Figure 6h).
DISCUSSION
Mutation of PTEN is associated with high-grade GBM formation.
mTORC2 is emerging as a potential drug target in PTEN-mutated
cancers. The detailed mechanism of molecular regulation and
cross-talk between PTEN and mTORC2 is still not clearly known.
Accordingly, we investigated the role of PTEN in mTORC2
regulation and signaling in GBM. The major achievement of this
study is providing evidence that PTENmu cells exhibit enhanced
mTORC2 formation and signaling because of the decreased
inhibitory phosphorylation of Rictor (Thr1135). This is the ﬁrst
evidence suggesting Thr1135 phosphorylation of Rictor is
controlled by PTEN, and demonstrates PTEN as the master
Figure 4. PTEN inhibits mTORC2 formation by hyperphosphorylation of Rictor at Threonine 1135 position. (a) PTENmu and PTENwt cells were
lysed for co-immunoprecipitation (co-IP) study. Protein was incubated with anti-mTOR antibody overnight at 4oC followed by incubation with
protein A-Sepharose 4B, washed with ice-cold phosphate-buffered saline (PBS). The immunocomplex was resolved by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) and subsequently identiﬁed using the respective antibodies. Co-IP revealed that
Raptor is associated with mTOR in both the cells, whereas Rictor is associated with mTOR only in PTENmu cells. (b) PTENwt cells were
transfected with siPTEN. After 24 h of transfection, cell lysates were subjected to co-IP analysis. Cells transfected with siPTEN showed increased
association of Rictor with mTOR. (c) Untreated PTENwt and PTENmu cell lysates were subjected for western blot analysis. Expression of
phosphorylated Rictor at Thr1135 was detected higher in PTENwt than PTENmu cells. (d, e) PTENwt cells were transfected with siPTEN. After
24 h of transfection cell lysates were subjected to western blot analysis. Status of Rictor phosphorylation at Thr1135 position was determined.
Densitometric analysis showed that there was about 35% reduction of phosphorylation of Rictor (Thr1135) after PTEN knockdown from
PTENwt cells. Each value is the mean± s.d. of three independent experiments. *Po0.05, signiﬁcant difference between two test groups.
(f) Other PTENmu (T98G, U373MG) and PTENwt (LN18) GBM cell lysates were prepared and subjected for western blot analysis. Status of Rictor
Thr1135 phosphorylation was compared. (g, h) PTENwt cells (8 ×105) were seeded and incubated for 24 h. Next, cells were transfected with
wild-type pRK-5/Rictor (myc-tag) or the T1135A mutant of pRK-5/Rictor (myc-tag, 2 μg/well) or empty vector alone. After 36 h of transfection,
cell lysates were prepared and subjected to co-IP (g) and western blot analysis (h). (g) Co-IP showed Rictor was associated with mTOR in cells
transfected with pRK-5/Rictor T1135A. (h) Immunoblot analysis showed the status of myc-tagged Rictor, p-AKT Ser473 and p-GSK3β Ser9 in
those transfected cells. (i) Schematic representation: PTEN-mediated regulation of mTORC2 formation and downstream signaling. (j, k) PTENwt
cells were transfected with siRaptor or co-transfected with siRaptor and siPTEN consecutively. After 24 h of transfection, cells were lysed and
subjected to western blot analysis. (j) Western blot showed the relative status of mTOR, p-mTOR, p-S6K1, Rictor, p-Rictor Thr1135, AKT, p-AKT
Ser473, Raptor and PTEN. (k) Densitometry analysis showing the fold change of p-mTOR Ser2481 and p-Rictor Thr1135. Each value is the
mean± s.d. of three independent experiments. *Po0.05, signiﬁcant difference between two test groups. In all the western blot experiments,
β-actin served as loading control.
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regulatory molecule in mTORC2 formation. In addition, we have
established mahanine, carbazole alkaloid from an edible plant, as
a potential mTORC1/2 inhibitor that showed cytotoxicity both in
PTENmu/PTENwt cells.
mTORC2 activity is required for generation of PTEN deletion-
induced prostate cancer.36 EGFRvIII-mediated activation of
mTORC2 was reversed by PTEN activity.37 A correlation between
PTEN and Rictor was also reported in leukemogenesis.38 Here we
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showed that PTENmu cells have higher mTORC2 formation and
downstream signaling than PTENwt cells as evidenced by
enhanced mTOR Ser2481, AKT Ser473 and GSK3β Ser9 phosphor-
ylations. Although a correlation between PTEN and AKT Ser473
phosphorylation was reported in lung cancer and rhabdomyo-
sarcomas, no cross-linking molecule between these phosphatase
and kinase was demonstrated.39,40 Here, we showed mTORC2 is a
connecting molecule between PTEN and AKT.
During exploration of mTORC1/2-associated molecules, we
observed that Rictor is differentially phosphorylated (Thr1135)
with respect to the functional existence of PTEN. Rictor
phosphorylation (Thr1135) is responsible for decreased activity
of mTORC2 and reduced AKT (Ser473) phosphorylation.34
Therefore, reduced mTORC2 activity and AKT Ser473 phosphor-
ylation in PTENwt cells is a consequence of increased Rictor
Thr1135 phosphorylation. This event was conﬁrmed when we
knocked down PTEN in PTENwt cells and observed reduced Rictor
phosphorylation, and as a consequence, enhanced mTORC2
signaling. Although Rictor Thr1135 phosphorylation is responsible
for decreased activity of mTORC2, reports suggest this had no
effect on mTORC2 complex formation.34,41–43 However, the
detailed mechanism behind reduced mTORC2 activity without
hampering mTORC2 complex formation was not revealed. Our
data revealed that not only was downstream signaling affected,
but also there was differential mTORC2 complex formation in
PTENwt and PTENmu cells. PTENwt cells lack signiﬁcant mTORC2
formation, and that was reverted with PTEN knockdown.
Therefore, we conclude that in the presence of PTENwt, there is
enhanced Rictor Thr1135 phosphorylation, decreased mTORC2
formation, which connected to lower AKT activity, and increased
GSK3β activity. The role of PTEN in regulating Thr1135 phosphor-
ylation and mTORC2 complex formation was further demon-
strated by expressing T1135A mutant Rictor in PTENwt cells.
We observed signiﬁcant mTORC2 complex formation and down-
stream signaling in the presence of PTEN when there was a
mutant Rictor that cannot be phosphorylated on Thr1135.
Therefore, we concluded that this may be a unique phenomenon
in GBM where phospho-Rictor Thr1135 could not be recruited to
mTORC2 in the presence of PTENwt.
Thr1135 phosphorylation of Rictor is also controlled by S6K1 via
mTORC1.34,43 This downstream kinase is known to be a linker
molecule between mTORC1/2. Therefore, we checked mTORC1
activity and found equivalent mTORC1 formation and downstream
activity as judged by comparable phosphorylation of downstream
signaling molecules (S6K1 and 4E-BP1). This data reconﬁrmed the
involvement of PTEN in regulation of mTORC2 in GBM. Therefore,
S6K1 may not be solely responsible for controlling Rictor (Thr1135)
phosphorylation. Simultaneous suppression of S6K1 activity and
functional PTEN in PTENwt cells completely abolishes Rictor
phosphorylation (Thr1135) and enhances active mTORC2
formation. However, PTEN, being a phosphatase, cannot phos-
phorylate a molecule directly. We assume that PTEN may be
affecting some other kinases by removing inhibitory phosphoryla-
tion, and they in turn phosphorylate Rictor at the speciﬁc site.
Alternatively, it may also be possible that PTEN dephosphorylates
some other site of Rictor that enables the molecule to change its
conformation in such a way so that the Thr1135 site is exposed for
further phosphorylation by known kinases like S6K1. Experiments
to distinguish between these possibilities are ongoing.
Basic understandings at the cellular and molecular level are
successful when a translational or therapeutic approach works out
positively. We have observed mahanine exerted cytotoxicity both
in PTENmu and PTENwt cells thus behaved as an mTORC1/2
inhibitor. However, in PTENwt cells, where mTORC2 was not
signiﬁcantly active and mTORC1 is predominant, mahanine
behaves like an mTORC1 inhibitor. Here we observed an activation
of the AKT pathway in PTENwt cells. Several reports indicated that
mTORC1 inhibition could lead to activation of AKT by other
pathways.35,44,45 This was due to release of the negative feedback
loop via S6K1 leading to the activation of PI3K/AKT pathway.44
mTORC1 inhibition also leads to MAPK pathway-dependant AKT
activation.45
This activation of AKT was reversed in PTENwt cells in the
presence of speciﬁc PI3K inhibitors. We also observed a synergistic
effect when a combination of mTORC1/2 and PI3K inhibitors were
used to overcome this AKT activity in PTENwt cells. These data
suggest that for an effective therapeutic strategy both mTORC1/2
and PI3K inhibitors may be necessary for a beneﬁcial effect in
PTENwt GBM.
Our ﬁndings demonstrated that PTEN behaved like a physio-
logical inhibitor of mTORC2 formation. Generation of mTORC2
upon PTEN depletion provided the speciﬁc target of mahanine
and hence cell death was increased in PTENwt cells.
We have observed a reciprocal relationship between mTORC2
and GSK3β in GBM. Therapeutically, we also proved this reciprocal
relationship. In PTENmu cells where mTORC2 and AKT are active
and GSK3β is inactive, treatment with GSK3β inhibitors did not
add any extra beneﬁt. In contrast, a GSK3β inhibitor exerted a
signiﬁcant effect on PTENwt cells where GSK3β is active.
Studies have suggested that mTORC1/C2 inhibitors have more
effect on PTEN-mutated cancers.46,47 Our results convincingly
showed the mechanism whereby PTEN mutations increase the
sensitivity of cancers to mTORC1/2 inhibitors. We have established
loss of PTEN induces more mTORC2 formation, and more
susceptible to mTORC1/2 inhibitors. This hypothesis was further
proven when we depleted Rictor from PTENmu cells, which had
abundant mTORC2 formation. Depletion of Rictor leads to
decreased mTORC2 formation, and therefore they behaved like
PTENwt cells, with predominant mTORC1. Accordingly, mTORC1/2
inhibitors acted as only mTORC1 inhibitors and we observed a
Figure 5. Mahanine, a novel mTORC1/2 inhibitor induces differential downstream regulation of mTORC in PTENmu and PTENwt cells. PTENmu
and PTENwt cells were treated with mahanine (Mh, 5-20 μM) alone or in combination with PI3K inhibitors namely LY294002 (LY, 20 μM) or
wortmannin (wort, 100 nM). After 24 h, cells were subjected to western blot and ﬂow cytometry analysis. (a) Immunoblot analysis showed
expression level of p-mTOR (Ser2448 and Ser2481) in mahanine (0–15 μM) treated PTENmu and PTENwt cells after 24 h. Both mTORC1 and
mTORC2-speciﬁc phosphorylations were disrupted at 15 μM of mahanine. (b) Status of AKT activity in mahanine (0–20 μM) treated PTENmu and
PTENwt cells after 24 h. AKT activity decreased as identiﬁed by phosphorylation at the sites of Thr308 and Ser473 in PTENmu cell. In contrast,
both the phosphorylation sites of AKT were hyperphosphorylated in mahanine-treated PTENwt cells. (c) The activity readout of mTORC1 as
judged by the phosphorylation of its downstream substrate S6K1 and 4E-BP1 after 24 h of mahanine treatment (0–15 μM) in PTENmu and
PTENwt cells. (d) Status of p-AKT in PTENwt cell, pre-treated with LY294002 in combination with mahanine. (e) Status of S6K1, 4E-BP1 and AKT
phosphorylation in PTENwt cell, pre-treated with PI3K inhibitor (wortmannin) in combination with mahanine. (f, g) PTENmu and PTENwt cells
were treated with different doses of mahanine (0–15 μM), LY294002 (0–30 μM) and wortmannin (50–150 nM) alone or in combination with
mahanine–LY294002 or mahanine–wortmannin. After 24 h of treatment, dead cell populations were determined by PI staining. (f) Mahanine
(12 μM) in combination with LY294002 (20 μM) showed synergistic cell death activity in PTENwt cells. (g) Mahanine (10 μM) in combination with
wortmannin (100 nM) showed synergistic cell death activity in PTENwt cells. Each value is the mean± s.d. of three independent experiments.
*Po0.05, signiﬁcant difference between two test groups.
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reduction in cell death. Therefore, mTORC2 is the prime factor that
is responsible for differential sensitivity to mTORC1/2 inhibitors.
PTEN showed its effect by inhibiting Rictor and thereafter mTORC2
kinase activity in PTENwt cells.
This observation was additionally conﬁrmed by using a well-
known mTORC1 inhibitor, rapamycin. Although rapamycin shows
cytotoxicity in PTENwt/PTENmu cells, however, these cells activate
AKT as evidenced by the enhanced Thr308 and Ser473
phosphorylation. Phosphorylation of 4E-BP1 remained unchanged
whereas S6K1 was decreased (Supplementary Figure S5).
Therefore, these data indicate again that not only mahanine but
other mTORC1 inhibitors also activate AKT in PTENwt cells. Most
importantly, a sole mTORC1 inhibitor can hyperphosphorylate AKT
irrespective of PTEN status.
To correlate our observation, we found that mahanine inhibited
AKT in two PTENmu prostate cancer cells.26,32 Mahanine, in
contrary, prevented palmitate-induced inhibition of the insulin-
stimulated phosphorylation of AKT in a PTENwt cell.48 According to
our hypothesis and ﬁndings, in PTENmu prostate cancer cells,
mahanine might inhibit AKT completely by suppressing both
Figure 6. Differential sensitivity of mTORC1/2 inhibitor and GSK3β inhibitor in PTENwt and PTENmu cells based on the existence of mTORC2.
(a, b) PTENwt cells were transfected with siPTEN and after 24 h, they were treated with mahanine (0–15 uM). (a) The expression levels of
phospho-AKT Ser473 were revealed by western blotting. (b) Dead cell population was determined by PI staining. (c, d) PTENmu cells were
transfected with siRictor and after 24 h, they were treated with mahanine (0–15 μM). (c) Mahanine-mediated cell death was determined by PI-
positive cells by ﬂow cytometric analysis. (d) Light microscopic image showed the morphology of PTENmu cells after mahanine treatment. (e)
Schematic diagram showed possible strategy to enhance the activity of mTORC1/2 inhibitor in GBM. (f, g) PTENmu and PTENwt cells were
treated with mahanine (12 μM) and GSK3β inhibitor (SB216763, 20 μM). After 24 h of treatment, cells were processed for cell cycle analysis.
Dead cell population was determined by PI staining by ﬂow cytometry. Each value is the mean± s.d. of three independent experiments.
*Po0.05, signiﬁcant difference between two test groups. (h) Schematic representation: reciprocal responsiveness of mahanine and GSK3β
inhibitor depending on existence of mTORC2 in PTENwt and PTENmu cells.
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mTORC1/2. In contrast, mTORC2 could not form in the PTENwt (L6)
cells and mahanine behaved like an mTORC1 inhibitor
and enhanced AKT activity by the inhibition of a negative
feedback loop.
Therefore, it is envisaged that PTEN-dependent mTORC1 and
mTORC2 dynamics are not restricted only to the GBM system and
could be a global phenomenon. Our ﬁndings will open up a new
avenue of thought for designing modiﬁed and efﬁcient therapy
against malignancy. However, more in-depth studies are needed




All the antibodies were from Cell Signaling Technology (Danvers, MA, USA):
mTOR (cat #2983), phospho-mTOR (Ser2481, cat #2974), phospho-mTOR
(Ser2448, cat #5536), Rictor (cat #9476), phospho-Rictor (Thr1135,
cat #3806), Raptor (cat #2280), AKT (cat #4691), phospho-AKT (Ser473,
cat #4060), phospho-AKT (Thr308, cat #13038), phospho-AKT (Thr450,
cat #9267), GSK-3β (cat #9315), phospho-GSK-3β (Ser9, cat #9336), PTEN
(cat #9559), β-actin (cat #4970), 4E-BP1 (cat #9644), phospho-4E-BP1
(Thr37/46, cat #2855), S6K1/p70S6K (cat #9202), phospho-S6K1/phospho-
p70S6K (Thr389, cat #9234), Myc-Tag (cat #2276), horseradish peroxidase-
linked anti-rabbit IgG (cat #7074), horseradish peroxidase-linked anti-
mouse IgG (cat #7076). Lipofectamine LTX, plus reagent, culture medium
were from Invitrogen (Carlsbad, CA, USA). Antibiotic–antimycotic,
propedium iodide (PI), rapamycin, GSK3β inhibitor (SB212763), PI3K
inhibitor (LY294002 and wortmannin) and other chemicals were from
Sigma–Aldrich (St Louis, MO, USA). Protease and phosphatase inhibitor
cocktails were from Calbiochem (San Diego, CA, USA). Cycle Test Plus kit
was from BD Bioscience (East Rutherford, NJ, USA). Super Signal West Pico
imaging system was from Thermo Scientiﬁc (Rockford, IL, USA).
Cell lines and culture condition
PTENmu (U87MG, T98G and U373MG) and PTENwt (LN229 and LN18)
human GBM cell lines (Supplementary Figure S4) were from ATCC
(Manassas, VA, USA) and mycoplasma contamination was checked. They
were cultured in Iscove's modiﬁed dulbecco's medium (IMDM) supple-
mented with 10% heat inactivated fetal bovine serum and 1% antibiotic–
antimycotic, and maintained at 37 oC with 5% CO2. For speciﬁc
experiments, cells (1 × 104− 1× 106) were treated with various inhibitors/
drugs under identical conditions.
Transfection, siRNA and plasmids
siRNA against human PTEN, Rictor and Raptor were from Ambion Life
Technologies, Carlsbad, CA, USA (Supplementary Figure S3). Vector
encoding myc-tag wild-type Rictor (pRK-5/Rictor) or T1135A mutated form
of Rictor (pRK-5/Rictor T1135A) was kind gift from Dr Philippe P Roux
(Faculty of Medicine, Universite´ de Montre´al, Montreal, Quebec, Canada).
PTENmu/PTENwt cells were transiently transfected with human PTEN/Rictor/
Raptor targeting siRNAs (Supplementary Figure S3) or pRK-5/Rictor or
pRK-5/Rictor T1135A or empty vector alone using lipofectamine LTX and
plus reagent following the manufacturer’s instruction. PTEN-depleted/
Figure 6. Continued.
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Rictor-depleted cells were further treated with inhibitors for 24 h and
processed for western blot and ﬂow cytometric analysis.25
Immunoblotting
Drug/inhibitor treated or siRNA/plasmid transfected or untreated/untrans-
fected cells were harvested and lysed and processed for western blot
analysis.25 Target proteins were identiﬁed by the West Pico chemiluminis-
cence detector system or Biorad ChemiDoc MP System (Bio-Rad, Hercules,
CA, USA). Developed bands were densitometrially analyzed by ImageJ
software (NIH, Bethesda, MD, USA).25
Co-immunoprecipitation and immunoprecipitation
For detection of the mTOR complexes, cells were lysed in ice by sonication
(Qsonica-LLC, XL-2000 series, Newtown, CT, USA). Protein (200 μg) was
incubated with anti-mTOR antibody (1:100) overnight at 4 oC. Immuno-
complex was incubated with protein A-sepharose 4B, washed with ice-cold
phosphate-buffered saline, resolved by sodium dodecyl sulfate–polyacry-
lamide gel electrophoresis and subsequently identiﬁed using the
respective antibodies.
Detection of cell death and cell cycle analysis by MTT assay and
ﬂow cytometry
Mahanine was puriﬁed as described previously.31 Cell viability of mahanine
(0–30 μM)-treated cells (1 × 104) was checked after 48 h. They were further
incubated with MTT (100 μg/ml) for 3 h. Formazan crystals were dissolved in
dimethylsulfoxide and optical density was taken at 550 nm.25 Cells (1 ×106)
were treated with mahanine, SB216763, Wortmanin and LY294002 alone or
in combination for 24 h and processed using Cell Cycle Test Plus kit.25 At
least, 20 000 cells were acquired and analyzed by ﬂow cytometry using
CellQuest Pro software (BD FACSCalibur, San Jose, CA, USA).49 Morphology of
mahanine-treated cells were imaged by transmitted light digital inverted
microscope (EVOS XL Core, Life Technology, Carlsbad, CA, USA).
Statistical analysis
All the data were from at least three independent experiments and
statistical analysis was performed using Graph Pad Prism 5 (La Jolla, CA,
USA). The differences between the groups were analyzed by two tail
Student's t-test or Mann–Whitney U-test. Standard error bars represent the
s.d. of the mean (± s.d.) and *Po0.05, denoted the signiﬁcant differences
between the means of the untreated and treated cells or two test groups.
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